These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23569370

  • 21. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
    Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A.
    Chest; 2014 May; 145(5):981-991. PubMed ID: 24385182
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 May; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C, Jia J, Dong K, Luo L, Wu K, Mehta R, Peng J, Ren Y, Gross A, Yu H.
    PLoS One; 2015 Jun; 10(3):e0121264. PubMed ID: 25816315
    [Abstract] [Full Text] [Related]

  • 25. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
    Condreay L, Huang L, Harris E, Brooks J, Riley JH, Church A, Ghosh S.
    Respir Med; 2016 May; 114():123-6. PubMed ID: 27109822
    [Abstract] [Full Text] [Related]

  • 26. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
    Hahn B, Hull M, Blauer-Peterson C, Buikema AR, Ray R, Stanford RH.
    Respir Med; 2018 Jun; 139():65-71. PubMed ID: 29858004
    [Abstract] [Full Text] [Related]

  • 27. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J.
    Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
    [Abstract] [Full Text] [Related]

  • 28. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

  • 29. The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.
    Requena G, Dedman D, Quint JK, Ghosh RE, Williams R, Pimenta JM.
    Int J Chron Obstruct Pulmon Dis; 2021 Oct; 16():629-642. PubMed ID: 33731992
    [Abstract] [Full Text] [Related]

  • 30. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
    Donohue JF, Niewoehner D, Brooks J, O'Dell D, Church A.
    Respir Res; 2014 Jul 11; 15(1):78. PubMed ID: 25015176
    [Abstract] [Full Text] [Related]

  • 31. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S, Lee LA, Sule N, Fowler A, Peachey G.
    Clin Pharmacokinet; 2021 Jul 11; 60(7):887-896. PubMed ID: 33598874
    [Abstract] [Full Text] [Related]

  • 32. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R, Norris V, Siederer S.
    Pulm Pharmacol Ther; 2013 Apr 11; 26(2):256-64. PubMed ID: 23232038
    [Abstract] [Full Text] [Related]

  • 33. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 11; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 34. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
    Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr 11; 13():203-215. PubMed ID: 29386889
    [Abstract] [Full Text] [Related]

  • 35. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
    Stanbrook MB.
    Ann Intern Med; 2015 Dec 15; 163(12):JC10. PubMed ID: 26666800
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan 15; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 37. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
    Mannino D, Bogart M, Germain G, Huang SP, Ismaila AS, Laliberté F, Jung Y, MacKnight SD, Stiegler MA, Duh MS.
    Int J Chron Obstruct Pulmon Dis; 2022 Jan 15; 17():491-504. PubMed ID: 35281476
    [Abstract] [Full Text] [Related]

  • 38. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I.
    Int J Chron Obstruct Pulmon Dis; 2016 Jan 15; 11():1413-24. PubMed ID: 27445468
    [Abstract] [Full Text] [Related]

  • 39. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E.
    Expert Rev Clin Pharmacol; 2014 Jul 15; 7(4):403-13. PubMed ID: 24909949
    [Abstract] [Full Text] [Related]

  • 40. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
    Mannino D, Bogart M, Wu B, Germain G, Laliberté F, MacKnight SD, Jung Y, Stiegler M, Duh MS.
    Respir Med; 2022 Jun 15; 197():106807. PubMed ID: 35429764
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.